About Antigen Express
Antigen Express is a Healthcare company based in Wellesley (United States) founded in 1993, and was acquired by Generex Biotechnology in June 2003. Antigen-specific immune modulation for cancers and autoimmune diseases is developed. The company has 1 employees. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Antigen Express was established in 1993 as a wholly owned subsidiary of Generex Biotechnology Corporation. Based in Wellesley, United States, the mid-stage biotech firm concentrates on antigen-specific immune stimulation and suppression. Therapies are being advanced for cancers and autoimmune diseases, with Phase II trials initiated for HER-2neu positive breast cancer and prostate cancer applications.
- Headquarters Wellesley, United States
- Employees 1
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website antigenexpress.com
- Social LinkedIn
- Acquired by Generex Biotechnology (Jun 2003)
- Investors
- Employee Count1
- Acquired byGenerex Biotechnology
(Jun 2003)
Investors in Antigen Express
Antigen Express has secured backing from 1 investor. Prominent investors backing the company include Generex Biotechnology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Technologies for large molecule drug delivery are developed. | 1983 | generex.com | Miramar, United States |
Investor details for Antigen Express
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Antigen Express
2 dated milestones of Antigen Express across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Antigen Express is founded.
- Exit Acquired by Generex Biotechnology.
Competitors of Antigen Express
Antigen Express has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Antigen Express
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Antigen Express (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Antigen Express
Complete news archive for Antigen Express
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Antigen Express
Antigen Express was founded in 1993.
Antigen Express is headquartered in Wellesley, United States. It is registered at Wellesley, Massachusetts, United States.
Antigen Express has 1 employees.
Antigen Express was established in 1993 as a wholly owned subsidiary of Generex Biotechnology Corporation. Based in Wellesley, United States, the mid-stage biotech firm concentrates on antigen-specific immune stimulation and suppression. Therapies are being advanced for cancers and autoimmune diseases, with Phase II trials initiated for HER-2neu positive breast cancer and prostate cancer applications.
Antigen Express's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Antigen Express has 1 investor. Key investors include Generex Biotechnology.
Yes. Antigen Express was acquired by Generex Biotechnology in June 2003.